1. Introduction {#s0005}
===============

In 5--10% of patients with amyotrophic lateral sclerosis (ALS), a positive family history for ALS can be detected (familial ALS, fALS) ([@b0060]), and the research field of ALS continues to develop rapidly with multiple disease gene discoveries ([@b0035]). An autosomal dominant inheritance of a GGGGCC hexanucleotide repeat in the first intron of the *C9orf72* gene is the most common cause of fALS in people of Northern European ancestry and is also a common cause of familial frontotemporal dementia (FTD) ([@b0045], [@b0200], [@b0065], [@b0205]). In the original publication describing that phosphorylated 43 kDa TAR DNA-binding protein (pTDP-43) pathology in ALS disseminates in a sequential pattern that permits recognition of four neuropathological stages ([@b0040]), the eleven cases with *C9orf72* repeat expansion displayed the same sequential spreading pattern as the nonexpansion cases despite a greater regional burden of lesions. The search for *in vivo* biomarkers of disease onset and progression in *C9orf72* repeat expansion carriers has yielded promising candidates, as summarized in a recent review ([@b0080]), with particular interest in neuroimaging as a biomarker because it offers -- beyond the correlation of neuropathological data and *ex vivo* MRI ([@b0190]) -- the option of visualizing pathological changes in the brains of living patients.

For the demonstration of cerebral TDP43 pathology according to the principles of the neuropathological staging concept of ALS ([@b0040], [@b0025], [@b0030]), a neuroimaging approach exists that uses a tract of interest (TOI)-based diffusion tensor imaging (DTI) analysis technique to demonstrate ALS-specific corticoefferent tract pathology *in vivo* ([@b0100], [@b0105]). In the current study, a DTI- and TOI-based analysis was performed in patients with fALS and *C9orf72* expansion, comparing their findings with healthy controls and genetic ALS patients with *SOD1* mutation, to investigate the *in vivo* correlates of the neuropathological propagation pattern.

2. Materials and methods {#s0010}
========================

2.1. Subjects and patient characteristics {#s0015}
-----------------------------------------

Forty-two patients with confirmed ALS mutations were included who clinically met the diagnostic criteria according to the El Escorial diagnostic criteria ([@b0120]). The fALS patients included 27 *C9orf72* expansion carriers and a control group with a different mutation, i.e., 15 *SOD1* mutation carriers. Four of the *C9orf72* expansion carriers fulfilled the criteria for ALS-FTD of the behavioral type (bvFTD) according to Rascovsky criteria ([@b0195]). Details of demographics, clinical data including ALS-FRS-R ([@b0050]), and disease duration for all groups are summarized in [Table 1](#t0005){ref-type="table"}.Table 1(A) Patients\' and controls\' gender, age, and scanner distribution. (B) Subjects\' characteristics including cognitive profile measured with the Edinburgh cognitive and behavioural ALS screen (ECAS) for statistical comparison.(A)gender (m/f)Age/yearsage range/yearsMRI scanner 1.5 T/3.0 T*C9orf72*17/1062 ± 1234--7822/5controls A23/959 ± 1624--8226/6p (*t*-test)0.470.49--0.98*SOD1*8/755 ± 1337--7912/3controls B12/954 ± 1424--7317/4p (*t*-test)0.690.90--0.94(B)ECAS total scorememoryvisuospatiallanguageVerbal fluencyexecutive functionALS-FRS-R median (range)dis.dur./months median (range)years of educationHandedness (right/left)site of onset (spinal/bulbar)*C9orf72*30 ± 813 ± 511 ± 222 ± 615 ± 530 ± 840 (34 -- 48)12 (3 -- 37)12.8 ± 3.826/1.18/9*SOD1*107 ± 816 ± 212 ± 124 ± 417 ± 4.338 ± 444 (29 -- 48)13 (4 -- 48)13.7 ± 3.313/2.15/0

FALS patients were compared with a group of 32 age- and gender-matched controls. Gross brain pathology, including vascular brain alterations, could be excluded by conventional MRI including fluid attenuated inversion recovery sequences. All control individuals lacked a family history of neuromuscular disease and had no history of neurologic, psychiatric, or other major medical illnesses and were recruited from among spouses of patients and by word of mouth.

All participants provided written informed consent for the study protocol according to institutional guidelines which had been approved by the Ethics Committee of Ulm University, Germany (No. 19/12).

2.2. Cognitive analysis {#s0020}
-----------------------

In patients, cognition was measured with the German version ([@b0130]) of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS) ([@b0005]) by a trained psychologist. The ECAS addresses cognitive domains of language, verbal fluency, executive functions (ALS specific functions), and memory and visuospatial functions (ALS non-specific functions). Using the ECAS behavioral score, patients' behavioral alterations were reported by primary caregivers. Statistics for neuropsychology were performed using Statistical package for Social Sciences (SPSS version 21.0 IBM). Cognitive performance between groups was calculated with ANOVA and post-hoc Scheffé. Threshold of p \< 0.05 was adopted for statistical significance.

2.3. Genetic analysis {#s0025}
---------------------

DNA was extracted from whole EDTA-containing venous blood samples as previously described: analysis of the *C9orf72* repeat length was performed by fragment length analysis and repeat-primed PCR (RP-PCR) using previously published primers ([@b0235]). Since PCR-based methods cannot determine the size of larger expanded repeat-alleles, samples with a sawtooth pattern in the RP-PCR were further analyzed using Southern blot ([@b0065]). *SOD1* genotyping was performed based on Sanger Sequencing using previously published primers ([@b0220]).

All *SOD1* mutations were missense mutations. The *SOD1*-patients had nine different mutations. The p.R116G mutation, the most frequent *SOD1* mutation in Germany, was represented four times, the p.H44R three times, and the p.V149A two times. Therefore we had a rather wide variety of *SOD1* mutations in our *SOD1* cohort. The number of repeats in the *C9orf72*-patients ranged from 750 to 3000. Given the heterogeneity in disease duration and rate of progression among different SOD1 mutations and the wide range of expansion lengths in our *C9orf72*-patients, we judge the results to be reliable independent of the type of *SOD1* mutations and the number of repeats in *C9orf72*.

The *SOD1*- as well as the *C9orf72*-associated ALS patients were from all over Germany. Two *C9orf72*-patients were from outside Germany, Austria and France, and one *SOD1*-patient was from Sweden. About 34% of the *C9orf72*-patients had a FTD co-morbidity, and one patient with a p.H49R mutation in *SOD1* presented symptoms that were consistent with a beginning bvFTD. The majority of the other family members with a *C9orf72* expansion had ALS alone, a subset of the index patients displayed cognitive or behavioural symptoms of FTD. ALS/FTD co-morbidity was rarely observed in those family members.

2.4. MRI acquisition {#s0030}
--------------------

MRI scans were obtained with two scanners, a 1.5 Tesla Magnetom Symphony and a 3.0 T head scanner Allegra (both, Siemens Medical, Erlangen, Germany). The 1.5 T DTI study protocol consisted of 52 volumes (64 slices, 128x128 pixels, slice thickness 2.8 mm, pixel size 2.0 mm × 2.0 mm), representing 48 gradient directions (b = 1000 s/mm^2^) and four scans with b = 0; TE and TR were 95 ms and 8000 ms. The 3.0 T DTI study protocol consisted of 49 volumes (52 slices, 96x128 pixels, slice thickness 2.2 mm, pixel size 2.2 mm × 2.2 mm), representing 48 gradient directions (b = 1000 s/mm^2^) and one scan with b = 0; TE and TR were 85 ms and 7600 ms.

2.5. Data analysis {#s0035}
------------------

The analysis of the DTI data was performed by use of the software *Tensor Imaging and Fiber Tracking* (TIFT -- [@b0135]). The algorithms used in this study have been previously described in detail ([@b0100], [@b0105], [@b0160]). Stereotaxic normalization to the Montreal Neurological Institute (MNI) space was performed iteratively using study-specific templates ([@b0145]). From the stereotaxically normalized DTI data sets of all subjects, fractional anisotropy (FA) maps were quantitatively calculated to map white matter microstructure ([@b0115]). A Gaussian filter of 8 mm full width at half maximum was applied for smoothing of FA maps for a good balance between sensitivity and specificity ([@b0215]). Finally, FA maps were corrected for the covariate age. Data were harmonized between the two scanners used ([@b0155]) -- the harmonization procedure has already been established at multicenter level cross-sectionally ([@b0150], [@b0155]) and longitudinally ([@b0090]). In addition, the ratio of scans acquired at each scanner was almost the same between the subject groups, i.e., the age-matched controls' data sets were matched to the ALS groups for number of scans at the different scanners (for details see [Table 1](#t0005){ref-type="table"}).

Statistical comparison by Student's *t*-test was performed voxel-wise for FA values to detect changes between the subject groups (whole brain-based spatial statistics, WBSS). Voxels with FA values below 0.2 were not considered for statistical comparison, since cortical grey matter shows FA values up to 0.2 ([@b0110]). Statistical results were corrected for multiple comparisons using the false-discovery-rate (FDR) algorithm at p \< 0.05 ([@b0085]). Further reduction of the alpha error was performed by a spatial correlation algorithm that eliminated isolated voxels or small isolated groups of voxels in the size range of the smoothing kernel leading to a threshold cluster size of 256 voxels ([@b0105]).

Defined tract systems according to the ALS-staging system ([@b0025], [@b0125]) were identified with the tract-of interest (TOI) approach ([@b0100], [@b0105]). TOIs for the four ALS stages were the corticospinal tract (CST, representative for stage 1), the corticorubral and corticopontine tracts (corresponding to stage 2), the corticostriatal pathway (stage 3), and the proximal perforant path (stage 4). As a reference path, a tract originating from the corpus callosum (CC) area V was used where no involvement in ALS-associated neurodegeneration could be anticipated. Tract-wise fractional anisotropy statistics (TFAS ([@b0140], [@b0150])) was performed by statistically comparing the FA values in each tract system between two subject groups (Student's *t*-test), not considering FA-values \< 0.2. The use of Student's *t*-test was justified since the groups were large enough to show a Gaussian distribution of FA values.

3. Results {#s0040}
==========

3.1. Whole brain-based spatial statistics of FA maps {#s0045}
----------------------------------------------------

The WBSS comparison at the group level for the 27 *C9orf72* fALS patients vs 32 controls demonstrated widespread regional alterations (cluster size 63709 mm^3^) at FDR-corrected p \< 0.05 ([Fig. 1](#f0005){ref-type="fig"}): FA reductions were observed mainly along the CST (corresponding to neuropathological stage 1 of ALS -- [@b0105]) with projections to frontal areas (corresponding to neuropathological stages 2 and 3) and to the hippocampal areas (corresponding to neuropathological stage 4).Fig. 1Whole brain-based spatial statistics (WBSS) of FA maps of fALS patients vs controls. WBSS of FA maps (p \< 0.05, False-discovery-rate (FDR) corrected) demonstrated one cluster of regional FA reductions for *C9orf72* fALS patients vs controls. The *SOD1* mutation did not show any significant cluster of FA reduction when compared to age- and gender-matched controls.

The comparison at the group level by WBSS for the 15 fALS patients with *SOD1* mutation vs 21 matched controls demonstrated no significant clusters of regional alterations at FDR-corrected p \< 0.05.

3.2. Differences of FA in the specific tract systems {#s0050}
----------------------------------------------------

The analysis of the FA differences in the ALS-related tract systems by use of TFAS showed significant differences of the averaged FA values between the *C9orf27* fALS patients and control groups. Changes were most prominent in the CST, followed by FA reductions in the corticorubral and corticopontine tracts (i.e., tracts related to ALS stages 1 and 2) ([Fig. 2](#f0010){ref-type="fig"}). Further FA reductions could be observed for the corticostriatal pathway and for the proximal perforant path (i.e., the tracts related to ALS stages 3 and 4). For the grand average of the stage-related tract systems, significant FA reductions were observed accordingly. TFAS showed no significant differences of the averaged FA values between the *SOD1* fALS patients and controls ([Fig. 2](#f0010){ref-type="fig"}). No significant FA alterations were observed in the reference path for any group comparison.Fig. 2Tractwise fractional anisotropy statistics (TFAS) of FA maps at the group level for fALS patients compared to controls. TFAS demonstrated significant regional FA reductions in ALS-related tract systems and in the grand average between *C9orf72* fALS patients and controls. *SOD1* mutation fALS patients did not show significant alterations when compared to age- and gender-matched controls. Error bars, SEM. \* p \< 0.05, \*\* p \< 0.001.

3.3. ALS staging at the individual level {#s0055}
----------------------------------------

ALS staging categorization was performed for all ALS patients, and 89% of the *C9orf72* fALS patients could be staged ([Supplementary Fig. 1](#s0085){ref-type="sec"}). After division into bulbar onset and spinal onset, the stage distribution of the spinal and bulbar onset was similar to the distribution of the whole group so that no significant difference in terms of staging could be observed between spinal and bulbar onset. The percentage of stageable C9orf72 fALS was higher than in previous studies in sporadic ALS patients ([@b0105]). In contrast, *SOD1*-associated fALS patients showed FA reductions along the CST compared to controls, but no significant changes of the other tract systems according to the staging scheme so that no staging categorization was possible in any of these fALS subjects. After division into bulbar onset and spinal onset, the stage distribution of the spinal and bulbar onset was similar to the distribution of the whole group so that no significant difference in terms of staging could be observed between spinal and bulbar onset.

3.4. Neuropsychology {#s0060}
--------------------

*C9orf72* patients performed worse in executive function (ANOVA F = 4.09, p = 0.03 with post-hoc Scheffé p = 0.041) and total score (trend ANOVA F = 3.06, p = 0.06 with post-hoc Scheffé p = 0.069) compared to *SOD1* patients. No differences between groups was observed for any of the other cognitive domains.

4. Discussion {#s0065}
=============

This DTI study with a TOI-based analysis showed the same corticoefferent tract involvement pattern according to the neuropathological staging scheme in fALS patients with *C9orf72* expansion as previously reported for a large group of sporadic ALS patients ([@b0105]), whereas this pattern could not be observed in ALS patients with *SOD1* mutation. On the basis of these neuroimaging data, the proposed staging scheme for ALS ([@b0025]) could be confirmed *in vivo* for fALS with *C9orf72* expansion, in analogy with the demonstration of corticofugal tract involvement in 'classical' ALS ([@b0100], [@b0105]) and in restricted ALS phenotypes ([@b0210], [@b0165], [@b0170], [@b0175], [@b0180]). Given that the neuropsychological results demonstrated that *C9orf72* patients performed significantly worse compared to *SOD1* patients, cognitive data underline the understanding that *C9orf72* ALS-patients resemble the subgroup within ALS that is closer to FTD according to neuropsychology than other genetic mutation carriers.

This is the first DTI study in patients with fALS with a hypothesis-guided TOI-based approach that addressed the white matter tracts corresponding to the pTDP-43-based neuropathology pattern. Previous data-driven DTI studies in fALS patients with *C9orf72* expansion in cross-sectional and longitudinal design demonstrated alterations in motor tracts, including the CST and the motor segment of the corpus callosum ([@b0080], [@b0010]) and in the frontal white matter ([@b0225]). In addition, further white matter areas and several white matter tracts were found to be affected: extensive cortico-striatal degeneration has been previously described in *C9orf72*-associated ALS, consistent with stage 3 ([@b0185]). Furthermore, extensive temporal lobe white matter alterations were also identified in *C9orf72* repeat carriers ([@b0020]). The current hypothesis-based approach was able to define an involvement pattern that *per se* did not differ from sporadic ALS patients but was identical to that proposed by the neuropathological data ([@b0040]). In contrast to the *C9orf72* expansion-associated fALS, the *SOD1*-associated fALS patients showed no TOI-based abnormalities, probably due to a different pattern of neuropathology. The lack of significant cerebral alterations in the *SOD1* patients is in accordance with a previous study in 20 patients with *SOD1*-associated ALS who demonstrated a relative preservation of brain motor structural networks as assessed by DTI ([@b0015]).

This study was not without limitations. First, the neuropathological confirmation of the neuroimaging transfer of the ALS propagation scheme in the brain by autopsy results was not available for the patients studied. A second drawback was the limited number of available genotyped fALS patients, although it seems safe to conclude that the data from the original neuropathological study ([@b0040]) were sufficient to be generalized for all *C9orf72* expansion-associated fALS cases. In addition, DTI data from two different scanners had to be included. However, given that controls and patients were equally distributed over scanner types, the group comparisons can be regarded as matched for scanner type. Finally, future studies should include longitudinal data to investigate the possibility of tracking disease propagation, as previously demonstrated for sporadic ALS patients ([@b0105]). Longitudinal tracking could optimally be performed in presymptomatic mutation carriers with respect to stagewise propagation, given that previous studies captured CST, CC and thalamic pathology long before projected symptom onset ([@b0230], [@b0070], [@b0055]).

In summary, the tract-specific DTI analysis demonstrated alterations of ALS-related tract systems for *C9orf72*-associated fALS and, thus, might be a promising candidate biomarker for patients with *C9orf72* repeat expansion ([@b0075]). Potentially, this approach will enable to detect effects of disease-modifying therapeutic interventions in the future, provided that the longitudinal TOI mapping reveals identical patterns as in sporadic ALS patients ([@b0105], [@b0095]). Perhaps even more importantly, persons known to carry the *C9orf72* expansion could receive MRI and TOI-based analyses at presymptomatic clinical stages in order to determine the time point in the disease course when the *in vivo* detection of the neuropathological disease stages is possible.
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